Dr. Suzanne Louise Bruhn Ph.D. serves as Independent Director of the Company. Dr. Bruhn has served as President and Chief Executive Officer of Tiaki Therapeutics Inc. since May 2019. Dr. Bruhn previously served as President and Chief Executive Officer of Proclara Biosciences, Inc. between April 2017 and September 2018. Dr. Bruhn previously served as President and Chief Executive Officer of Promedior, Inc. between May 2012 and November 2015. Prior to that, Dr. Bruhn served as Senior Vice President, Strategic Planning and Program Management at Shire plc, a publicly traded biopharmaceutical company, between December 1998 and February 2012. Dr. Bruhn previously served on the boards of directors of Raptor Pharmaceuticals Corp. and Novelion Therapeutics, Inc., both publicly traded pharmaceutical companies, Dr. Bruhn currently serves on the boards of directors of Pliant Therapeutics and Retrophin, Inc. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Bruhn is qualified to serve on our board of directors because of her expertise and experience in the biopharmaceutical industry, including her expertise in the development and commercialization of treatments for rare diseases.
As the Independent Director of Aeglea BioTherapeutics Inc, the total compensation of Suzanne Bruhn at Aeglea BioTherapeutics Inc is $99,309. There are 7 executives at Aeglea BioTherapeutics Inc getting paid more, with Anthony Quinn having the highest compensation of $2,482,780.
Suzanne Bruhn is 56, he's been the Independent Director of Aeglea BioTherapeutics Inc since 2017. There are 4 older and 10 younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.
Suzanne's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... und Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: